What is NGeneBio?
Headquartered in Seoul, South Korea, NGeneBio operates at the intersection of biotechnology and advanced software engineering. Founded in 2015 as a joint venture between Genecurix and Korea Telecom, the company specializes in the development of NGS-based in vitro diagnostics (IVD) panels and proprietary clinical analysis software. By integrating bioinformatics with clinical validation, NGeneBio provides essential tools for hereditary cancer screening and companion diagnostics (CDx). Their product portfolio, including the BRCAaccuTest and NGeneAnalysis platform, serves as a critical infrastructure for healthcare providers seeking to implement data-driven oncology solutions. The company's unique positioning as a bridge between telecommunications-backed data processing and molecular biology allows it to maintain a competitive edge in the high-growth diagnostics sector.
How much funding has NGeneBio raised?
NGeneBio has raised a total of $32M across 1 funding round:
Stock Offering
$32M
Stock Issuance/Offering (2021): $32M, investors not publicly disclosed
Key Investors in NGeneBio
Undisclosed Investor
An undisclosed institutional partner providing strategic capital to support the scaling of molecular diagnostic technologies.
Undisclosed Investor
A private equity participant focused on the long-term growth of high-tech medical device and software firms.
Undisclosed Investor
A strategic backer specializing in the intersection of telecommunications and biotechnology infrastructure.
What's next for NGeneBio?
With the recent influx of capital, NGeneBio is well-positioned to scale its operations and broaden its clinical diagnostic pipeline. The strategic roadmap focuses on the commercialization of solid tumor and hematologic cancer NGS panels, alongside the continued enhancement of its bioinformatics software suite. By leveraging its established clinical data analysis platform, the company aims to deepen its penetration into international markets, particularly where the demand for standardized, high-throughput genomic testing is rising. Future growth will likely be driven by the convergence of innovative software development and the expansion of its CDx offerings, ensuring that NGeneBio remains at the forefront of the global molecular diagnostics industry as it transitions into its next phase of enterprise-level maturity.
See full NGeneBio company page
